Halozyme Therapeutics Inc (HALO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $11.43B
Last updated: Nov 17, 2026 at 11:06 AM ET
Halozyme Therapeutics Inc (HALO) Stock Forecast
Analysts expect Halozyme Therapeutics (HALO) to earn $8.89 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.90B. Of 9 analysts, 7 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 78% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 22.2% |
| Buy | 5 | 55.6% |
| Hold | 2 | 22.2% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 19.1% and revenue estimates rise 14.7%.
- Fiscal year ending Dec 31, 2026
- $8.89
- EPS consensus, revenue $1.90B
- Fiscal year ending Dec 31, 2027
- $10.59
- EPS consensus, revenue $2.18B
- Next report
- Jan 26, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $8.89 | $8.73 to $9.04 | 6 | $1.90B | $1.88B to $1.93B | 9 |
| Dec 31, 2027 | $10.59 | $9.60 to $11.48 | 5 | $2.18B | $2.09B to $2.35B | 8 |
Quarterly Estimates
The EPS consensus falls from $2.70 for the quarter ending Dec 31, 2026 to $2.33 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.70 | $2.53 to $2.92 | 11 | $560.07M | $529.20M to $603.03M | 9 |
| Mar 31, 2027 | $2.33 | $2.32 to $2.34 | 3 | $488.72M | $478.00M to $499.43M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 7 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 1 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 3.6% from $8.58.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $8.89 | $8.84 | $8.58 | $8.58 | $8.58 | +3.6% |
| Fiscal year ending Dec 31, 2027 | $10.59 | $10.68 | $10.39 | $10.39 | $10.39 | +1.9% |
| Quarter ending Mar 31, 2027 | $2.33 | $2.33 | $2.34 | $2.34 | $2.34 | -0.4% |
Frequently Asked Questions About HALO
What is the HALO stock forecast?
Consensus analyst estimates put Halozyme Therapeutics's EPS at $8.89 for the fiscal year ending Dec 31, 2026, on revenue of $1.90B. The consensus rating from 9 analysts is Buy.
How do analysts rate HALO stock?
Of 9 analysts covering Halozyme Therapeutics, 2 rate it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from HALO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $8.89, with estimates from $8.73 to $9.04 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $10.59, with estimates from $9.60 to $11.48 from 5 analysts.
What revenue do analysts expect from Halozyme Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.90B, with estimates from $1.88B to $1.93B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.18B, with estimates from $2.09B to $2.35B.
How many analysts cover HALO?
9 analysts rate Halozyme Therapeutics stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
HALO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors